| DB ID | MyCo_3251 |
| Title | Serum markers as an aid in the diagnosis of pulmonary fungal infections in AIDS patients |
| Year | 2017 |
| PMID | 28759746 |
| Fungal Diseases involved | Pneumocystosis |
| Associated Medical Condition | HIV-AIDS |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The Ethical Committee approved this study (No. 8876/2012) and all patients signed the informed consent form. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | Here conducted a prospective cross-sectional study, from 2012 to 2016, at the Hospital das Clinicas of the University of Cam- pinas (UNICAMP), Sao Paulo, Brazil, which is the reference hospital for more than six million inhabitants. 60 patients were included in the study. The patients were classified in three groups: Pneumocystis jirovecii pneumonia (19 patients), community-acquired pneumonia (18 patients), and other infections (23 patients). |
| Cohort No. | 60 |
| Age Group | None |
| P Value | p<0.0001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay,LDH assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
